3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
32
Hodgkin Disease
29
Lymphoma
10
Sarcoma
7
Uveal Melanoma
5
Neoplasm Metastasis
4
Neoplasms
3
Leiomyosarcoma
2
HIV Infections
2
Solitary Fibrous Tumors
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Lymphoma, T-Cell, Peripheral
1
Immunotherapy
1
Hyperthermia
1
Hematologic Diseases
1
Carcinoma
1
Advanced Melanoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-Related Complex
1
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
Dacarbazine
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled